Table 2 Risk factors for OS and PFS in HBsAg + DLBCL patients
Parameters | OS | PFS | ||||||
|---|---|---|---|---|---|---|---|---|
Univariant | Multivariant | Univariant | Multivariant | |||||
HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P* | |
Females | 1.989 (1.039–3.810) | 0.038 | 2.035 (1.040–3.981) | 0.038 | 1.743 (0.915–3.321) | 0.091 | 2.137 (1.088–4.199) | 0.027 |
Age > 60 years | 2.016 (1.039–3.913) | 0.038 | 2.496 (1.188–5.245) | 0.016 | 1.831 (0.946–3.543) | 0.073 | 2.281 (1.085–4.795) | 0.030 |
Rituximab included | 0.361 (0.170–0.766) | 0.008 | 0.198 (0.081–0.485) | < 0.001 | 0.331 (0.155–0.706) | 0.004 | 0.161 (0.065–0.398) | < 0.001 |
Ann Arbor stage III/IV | 0.950 (0.494–1.826) | 0.878 | 0.460 (0.179–1.183) | 0.107 | 1.108 (0.577–2.125) | 0.758 | 0.523 (0.211–1.293) | 0.160 |
Positive B symptoms | 1.167 (0.612–2.227) | 0.639 | / | / | 1.247 (0.654–2.377) | 0.503 | / | / |
Liver involvement | 1.015 (0.244–4.224) | 0.984 | / | / | 1.037 (0.249–4.317) | 0.960 | / | / |
Spleen involvement | 0.841 (0.385–1.836) | 0.664 | / | / | 0.854 (0.390–1.872) | 0.693 | / | / |
Extranodal involvement ≥ 2 | 0.988 (0.505–1.933) | 0.973 | / | / | 1.112 (0.567–2.181) | 0.757 | / | / |
ECOG score ≥ 2 | 2.689 (1.267–5.705) | 0.010 | 2.157 (0.867–5.367) | 0.098 | 3.595 (1.664–7.767) | 0.001 | 2.934 (1.177–7.316) | 0.021 |
GCB subtype | 1.203 (0.623–2.323) | 0.581 | 0.731 (0.323–1.658) | 0.454 | 1.313 (0.681–2.533) | 0.416 | 0.718 (0.300–1.719) | 0.457 |
Elevated LDH | 2.158 (1.137–4.095) | 0.019 | 3.675 (1.342–10.059) | 0.011 | 2.561 (1.342–4.888) | 0.004 | 3.357 (1.234–9.130) | 0.018 |
IPI ≥ 3 | 1.921 (0.992–3.719) | 0.053 | 0.893 (0.268–2.631) | 0.763 | 2.128 (1.100–4.119) | 0.025 | 1.068 (0.352–3.242) | 0.907 |
Anti-HBV | 0.600 (0.288–1.248) | 0.171 | 0.336 (0.143–0.788) | 0.012 | 0.740 (0.356–1.535) | 0.418 | 0.397 (0.171–0.925) | 0.032 |